Considering RAGE as a potential master regulator of several processes that play a crucial role in development of psoriatic plaques, such as secretion of proinflammatory cytokines (17, 18) and migration of T-cells to the sites of skin damage (13, 14) we believe that the development of novel medications that target RAGE and RAGE-dependent signaling mechanisms can be beneficial for all psoriasis patients. The gene discussed is AGER; the disease is psoriasis.